Q-Line Biotech Ltd IPO
Price Band
₹326 – ₹343
Issue Size
₹214.48 Cr
Lot Size
400 shares
Min ₹1,37,200
Issue Dates
21 May – 25 May 2026
Listing Date
29 May 2026
About Q-Line Biotech Ltd
Q-Line Biotech Ltd is engaged in the development, manufacturing, and marketing of in-vitro diagnostic (IVD) products, including reagents, kits, point-of-care (POC) devices, and consumables. The company also manufactures, imports, and distributes diagnostic equipment used in clinical chemistry, haematology, immunodiagnostics, and molecular diagnostics. Its products are supplied to diagnostic centers, hospitals, and medical institutions across India through a strong distribution network. The company operates with in-house manufacturing capabilities, R&D focus, and third-party collaborations to support large-scale production of diagnostic solutions.
Visit WebsiteIPO Details
| Price Band | ₹326 – ₹343 |
| Face Value | ₹10 |
| Lot Size | 400 shares(Min ₹1,37,200) |
| Issue Size | ₹214.48 Cr |
| Fresh Issue | ₹214.48 Cr |
| Total Shares Offered | 62,53,200 |
| Listed On | NSE |
Objects of the Issue
The company proposes to utilise the net proceeds towards working capital requirements, repayment or prepayment of certain borrowings in part or full, and general corporate purposes. A major portion of funds will be used to strengthen operations in manufacturing and expansion of in-vitro diagnostic (IVD) product capacity.
Key Financial Metrics
EPS (Basic)
₹22.64
ROE
16.88%
ROCE
13.32%
Debt / Equity
1.06
Financial Performance
| Particulars (₹ Cr) | FY23 | FY24 | FY25 | 9M FY26 |
|---|---|---|---|---|
| Revenue | 184.81 | 206.45 | 322.58 | 236.5 |
| EBITDA | 32.98 | 37.63 | 71.32 | 64.23 |
| PAT | 32.1 | 34.44 | 28.13 | 38.69 |
| Total Assets | 251.58 | 339.25 | 455.49 | 561.34 |
| Net Worth | 127.37 | 161.81 | 189.95 | -0.04 |
| Total Borrowings | 73.65 | 96.91 | 164.95 | 243.85 |
Valuation
Market Capitalisation
P/E Ratio
Promoter Holding
Public Holding
Lot Size & Allocation
Investment by Category
| Category | Lot Size | Min Investment | Max Investment |
|---|---|---|---|
| S-HNI | 3 × 400 | ₹4,11,600 | ₹9,60,400 |
| B-HNI | 8 × 400 | ₹10,97,600 | — |
| Retail (RII) | 400 shares | ₹1,37,200 | ₹2,74,400 |
Registrar & Lead Managers
Registrar
Lead Managers (2)
Anchor Investors
| # | Investor | Type | Shares | Amount (₹ Cr) | % of Issue |
|---|---|---|---|---|---|
| 1 | Anchor Book (Aggregated QIB Participants) | QIB Anchor Investors | 17,49,277 | 60 | 28.48% |
Peer Comparison
| Company | Listed | Mkt Cap (₹ Cr) | EPS (₹) | P/E | ROE % |
|---|---|---|---|---|---|
| Q-Line Biotech Ltd IPO (this IPO) | — | 5,714.48 | ₹22.64 | — | 16.88% |
| Transasia Bio-Medicals Ltd | No | 3,500 | ₹18.4 | 22.5x | 16.2% |
| Trivitron Healthcare Pvt Ltd | No | 4,200 | ₹20.1 | 24.8x | 17.3% |
| Agappe Diagnostics Ltd | No | 2,800 | ₹15.6 | 20.9x | 14.8% |
| J Mitra & Co Pvt Ltd | No | 3,100 | ₹17.25 | 23.1x | 15.4% |
| Erba Diagnostics Mannheim (India) | No | 2,600 | ₹14.9 | 19.6x | 13.7% |
Data as of 19/5/2026
Frequently Asked Questions
15 questions about Q-Line Biotech Ltd IPO IPO
Important Dates
Community Discussion
Ask questions and share your thoughts about this IPO
Be the first to ask or share about Q-Line Biotech Ltd IPO